PARP-话题@MedSci

#PARP#

95篇内容 | 2757人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1621317, encodeId=afa3162131e3b, content=<a href='/topic/show?id=49b313e56ad' target=_blank style='color:#2F92EE;'>#PARP#</a>, objectTitle=Nat Commu：PARP抑制剂成功阻断前列腺癌的复发, objectType=article, longId=112120, objectId=a1d8112120e7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a1d8112120e7, replyNumber=0, likeNumber=77, createdTime=2017-09-07, rootId=0, userName=lishiwen, userId=fd4d20248280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a1d8112120e7, moduleTitle=Nat Commu：PARP抑制剂成功阻断前列腺癌的复发, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a1d8112120e7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621316, encodeId=0833162131641, content=<a href='/topic/show?id=49b313e56ad' target=_blank style='color:#2F92EE;'>#PARP#</a>, objectTitle=Nat Commun：前列腺癌中雄激素受体信号途径和PARP通路之间的合成致死作用, objectType=article, longId=111760, objectId=20b0111e6077, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=20b0111e6077, replyNumber=0, likeNumber=0, createdTime=2017-09-04, rootId=0, userName=lishiwen, userId=fd4d20248280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=20b0111e6077, moduleTitle=Nat Commun：前列腺癌中雄激素受体信号途径和PARP通路之间的合成致死作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=20b0111e6077)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621315, encodeId=7c57162131508, content=<a href='/topic/show?id=49b313e56ad' target=_blank style='color:#2F92EE;'>#PARP#</a>, objectTitle=Oncotarget：PARP1表达和TP53状态是区分胶质母细胞瘤亚型可靠标记物, objectType=article, longId=111113, objectId=6a2711111356, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6a2711111356, replyNumber=0, likeNumber=61, createdTime=2017-08-30, rootId=0, userName=lishiwen, userId=fd4d20248280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6a2711111356, moduleTitle=Oncotarget：PARP1表达和TP53状态是区分胶质母细胞瘤亚型可靠标记物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6a2711111356)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621314, encodeId=972c162131488, content=<a href='/topic/show?id=49b313e56ad' target=_blank style='color:#2F92EE;'>#PARP#</a>, objectTitle=ASCO：奥拉帕尼可延缓BRCA相关的转移性乳腺癌进展 ——PARP抑制剂有望在乳腺癌治疗中扮演重要角色, objectType=article, longId=100821, objectId=b7a5100821c6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b7a5100821c6, replyNumber=0, likeNumber=103, createdTime=2017-06-07, rootId=0, userName=lishiwen, userId=fd4d20248280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b7a5100821c6, moduleTitle=ASCO：奥拉帕尼可延缓BRCA相关的转移性乳腺癌进展 ——PARP抑制剂有望在乳腺癌治疗中扮演重要角色, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b7a5100821c6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621313, encodeId=89631621313bc, content=<a href='/topic/show?id=49b313e56ad' target=_blank style='color:#2F92EE;'>#PARP#</a>, objectTitle=ACCR年会：联合用药提高PARP抑制剂在耐药卵巢癌中的应答, objectType=article, longId=94582, objectId=a8609458271, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a8609458271, replyNumber=0, likeNumber=65, createdTime=2017-04-05, rootId=0, userName=lishiwen, userId=fd4d20248280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a8609458271, moduleTitle=ACCR年会：联合用药提高PARP抑制剂在耐药卵巢癌中的应答, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a8609458271)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621312, encodeId=cc5916213122b, content=<a href='/topic/show?id=49b313e56ad' target=_blank style='color:#2F92EE;'>#PARP#</a>, objectTitle=Science：《科学》癌症特刊—PARP抑制剂深度盘点, objectType=article, longId=93918, objectId=0c4c939184f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0c4c939184f, replyNumber=0, likeNumber=81, createdTime=2017-03-31, rootId=0, userName=lishiwen, userId=fd4d20248280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0c4c939184f, moduleTitle=Science：《科学》癌症特刊—PARP抑制剂深度盘点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0c4c939184f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621311, encodeId=7ce016213115b, content=<a href='/topic/show?id=49b313e56ad' target=_blank style='color:#2F92EE;'>#PARP#</a>, objectTitle=FDA批准第三个PARPi卵巢癌新药niraparib, objectType=article, longId=93844, objectId=f2fd938442c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f2fd938442c, replyNumber=0, likeNumber=64, createdTime=2017-03-30, rootId=0, userName=lishiwen, userId=fd4d20248280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f2fd938442c, moduleTitle=FDA批准第三个PARPi卵巢癌新药niraparib, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f2fd938442c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621310, encodeId=7f561621310cf, content=<a href='/topic/show?id=49b313e56ad' target=_blank style='color:#2F92EE;'>#PARP#</a>, objectTitle=Nat Med：20% 乳腺癌患者中可以 PARP 抑制剂治疗治疗中获益, objectType=article, longId=91888, objectId=cfab9188863, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cfab9188863, replyNumber=0, likeNumber=64, createdTime=2017-03-17, rootId=0, userName=lishiwen, userId=fd4d20248280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cfab9188863, moduleTitle=Nat Med：20% 乳腺癌患者中可以 PARP 抑制剂治疗治疗中获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cfab9188863)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621309, encodeId=92911621309ff, content=<a href='/topic/show?id=49b313e56ad' target=_blank style='color:#2F92EE;'>#PARP#</a>, objectTitle=FDA批准Clovis PARP抑制剂rucaparib, objectType=article, longId=84882, objectId=d7298488274, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d7298488274, replyNumber=0, likeNumber=70, createdTime=2016-12-22, rootId=0, userName=lishiwen, userId=fd4d20248280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d7298488274, moduleTitle=FDA批准Clovis PARP抑制剂rucaparib, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d7298488274)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621308, encodeId=f2a81621308d9, content=<a href='/topic/show?id=49b313e56ad' target=_blank style='color:#2F92EE;'>#PARP#</a>, objectTitle=喜讯！雅培生命旗下PARP抑制剂veliparib获美国FDA孤儿药资格认定, objectType=article, longId=82037, objectId=85118203ef1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=85118203ef1, replyNumber=0, likeNumber=104, createdTime=2016-11-11, rootId=0, userName=lishiwen, userId=fd4d20248280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=85118203ef1, moduleTitle=喜讯！雅培生命旗下PARP抑制剂veliparib获美国FDA孤儿药资格认定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=85118203ef1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621307, encodeId=7e8b162130ec6, content=<a href='/topic/show?id=49b313e56ad' target=_blank style='color:#2F92EE;'>#PARP#</a>, objectTitle=PARP抑制剂：是昙花一现还是开启新篇章, objectType=article, longId=73345, objectId=0bcee334526, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0bcee334526, replyNumber=0, likeNumber=72, createdTime=2016-07-22, rootId=0, userName=lishiwen, userId=fd4d20248280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0bcee334526, moduleTitle=PARP抑制剂：是昙花一现还是开启新篇章, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0bcee334526)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621306, encodeId=4872162130616, content=<a href='/topic/show?id=49b313e56ad' target=_blank style='color:#2F92EE;'>#PARP#</a>, objectTitle=AACR 2015：PARP抑制剂（奥拉帕尼）对晚期前列腺癌可能有效, objectType=article, longId=50147, objectId=94725014ec7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=94725014ec7, replyNumber=0, likeNumber=0, createdTime=2015-05-03, rootId=0, userName=lishiwen, userId=fd4d20248280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=94725014ec7, moduleTitle=AACR 2015：PARP抑制剂（奥拉帕尼）对晚期前列腺癌可能有效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=94725014ec7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621305, encodeId=ea98162130565, content=<a href='/topic/show?id=49b313e56ad' target=_blank style='color:#2F92EE;'>#PARP#</a>, objectTitle=Nat Rev Drug Discov：欧洲监管机构批准的第一个PARP抑制剂, objectType=article, longId=43657, objectId=68b54365ec8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=68b54365ec8, replyNumber=0, likeNumber=60, createdTime=2014-12-07, rootId=0, userName=lishiwen, userId=fd4d20248280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=68b54365ec8, moduleTitle=Nat Rev Drug Discov：欧洲监管机构批准的第一个PARP抑制剂, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=68b54365ec8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621304, encodeId=ca27162130498, content=<a href='/topic/show?id=49b313e56ad' target=_blank style='color:#2F92EE;'>#PARP#</a>, objectTitle=Cell Rep：有效治疗白血病的潜在药物——PARP抑制剂, objectType=article, longId=39659, objectId=3bf839659d3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3bf839659d3, replyNumber=0, likeNumber=94, createdTime=2014-08-29, rootId=0, userName=lishiwen, userId=fd4d20248280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3bf839659d3, moduleTitle=Cell Rep：有效治疗白血病的潜在药物——PARP抑制剂, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3bf839659d3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621303, encodeId=4c041621303e0, content=<a href='/topic/show?id=49b313e56ad' target=_blank style='color:#2F92EE;'>#PARP#</a>, objectTitle=Science：研究者揭示抑制癌症的新靶点PARP-1, objectType=article, longId=6505, objectId=afc96505af, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=afc96505af, replyNumber=0, likeNumber=125, createdTime=2012-05-26, rootId=0, userName=lishiwen, userId=fd4d20248280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=afc96505af, moduleTitle=Science：研究者揭示抑制癌症的新靶点PARP-1, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=afc96505af)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

PARP

2020-05-29

lishiwen (审核中...)

前往app查看评论内容

#PARP#

Nat Commu：PARP抑制剂成功阻断前列腺癌的复发

2017-09-07

lishiwen (审核中...)

前往app查看评论内容

#PARP#

Nat Commun：前列腺癌中雄激素受体信号途径和PARP通路之间的合成致死作用

2017-09-04

lishiwen (审核中...)

前往app查看评论内容

#PARP#

Oncotarget：PARP1表达和TP53状态是区分胶质母细胞瘤亚型可靠标记物

2017-08-30

lishiwen (审核中...)

前往app查看评论内容

#PARP#

ASCO：奥拉帕尼可延缓BRCA相关的转移性乳腺癌进展 ——PARP抑制剂有望在乳腺癌治疗中扮演重要角色

2017-06-07

lishiwen (审核中...)

前往app查看评论内容

#PARP#

ACCR年会：联合用药提高PARP抑制剂在耐药卵巢癌中的应答

2017-04-05

lishiwen (审核中...)

前往app查看评论内容

#PARP#

Science：《科学》癌症特刊—PARP抑制剂深度盘点

2017-03-31

lishiwen (审核中...)

前往app查看评论内容

#PARP#

FDA批准第三个PARPi卵巢癌新药niraparib

2017-03-30

lishiwen (审核中...)

前往app查看评论内容

#PARP#

Nat Med：20% 乳腺癌患者中可以 PARP 抑制剂治疗治疗中获益

2017-03-17

lishiwen (审核中...)

前往app查看评论内容

#PARP#

FDA批准Clovis PARP抑制剂rucaparib

2016-12-22

lishiwen (审核中...)

前往app查看评论内容

#PARP#

喜讯！雅培生命旗下PARP抑制剂veliparib获美国FDA孤儿药资格认定

2016-11-11

lishiwen (审核中...)

前往app查看评论内容

#PARP#

PARP抑制剂：是昙花一现还是开启新篇章

2016-07-22

lishiwen (审核中...)

前往app查看评论内容

#PARP#

AACR 2015：PARP抑制剂（奥拉帕尼）对晚期前列腺癌可能有效

2015-05-03

lishiwen (审核中...)

前往app查看评论内容

#PARP#

Nat Rev Drug Discov：欧洲监管机构批准的第一个PARP抑制剂

2014-12-07

lishiwen (审核中...)

前往app查看评论内容

#PARP#

Cell Rep：有效治疗白血病的潜在药物——PARP抑制剂

2014-08-29

lishiwen (审核中...)

前往app查看评论内容

#PARP#

Science：研究者揭示抑制癌症的新靶点PARP-1

2012-05-26

科室
- - 订阅+
  - 更多科室
工具
服务